1.Use of Antithrombin and Thrombomodulin in the Management of Disseminated Intravascular Coagulation in Patients with Acute Cholangitis.
Kazunari NAKAHARA ; Chiaki OKUSE ; Seitaro ADACHI ; Keigo SUETANI ; Sarika KITAGAWA ; Miki OKANO ; Yosuke MICHIKAWA ; Rei TAKAGI ; Ryuta SHIGEFUKU ; Fumio ITOH
Gut and Liver 2013;7(3):363-370
BACKGROUND/AIMS: To evaluate the usefulness and safety of treating disseminated intravascular coagulation (DIC) complicating cholangitis primarily with antithrombin (AT) and thrombomodulin (rTM). METHODS: A DIC treatment algorithm was determined on the basis of plasma AT III levels at the time of DIC diagnosis and DIC score changes on treatment day 3. Laboratory data and DIC scores were assessed prospectively at 2-day intervals. RESULTS: DIC reversal rates >75% were attained on day 7. In the DIC reversal group, statistically significant differences from baseline were observed in interleukin-6 and C-reactive protein levels within 5 days. Patients with no DIC score improvements after treatment with AT alone experienced slow improvement on a subsequent combination therapy with rTM. Although a subgroup with biliary drainage showed greater improvement in DIC scores than did the nondrainage subgroup, the mean DIC score showed improvement even in the nondrainage subgroup alone. Gastric cancer bleeding that was treated conservatively occurred in one patient. As for day 28 outcomes, three patients died from concurrent malignancies. CONCLUSIONS: Although this algorithm was found to be useful and safe for DIC patients with cholangitis, it may be better to administer rTM and AT simultaneously from day 1 if the plasma AT III level is less than 70%.
Antithrombin III
;
Antithrombins
;
C-Reactive Protein
;
Cholangitis
;
Dacarbazine
;
Disseminated Intravascular Coagulation
;
Drainage
;
Hemorrhage
;
Humans
;
Interleukin-6
;
Plasma
;
Prospective Studies
;
Stomach Neoplasms
;
Thrombomodulin
2.A multicenter comparative study of endoscopic ultrasound-guided fine-needle biopsy using a Franseen needle versus conventional endoscopic ultrasound-guided fine-needle aspiration to evaluate microsatellite instability in patients with unresectable pancreatic cancer
Tadayuki TAKAGI ; Mitsuru SUGIMOTO ; Hidemichi IMAMURA ; Yosuke TAKAHATA ; Yuki NAKAJIMA ; Rei SUZUKI ; Naoki KONNO ; Hiroyuki ASAMA ; Yuki SATO ; Hiroki IRIE ; Jun NAKAMURA ; Mika TAKASUMI ; Minami HASHIMOTO ; Tsunetaka KATO ; Ryoichiro KOBASHI ; Yuko HASHIMOTO ; Goro SHIBUKAWA ; Shigeru MARUBASHI ; Takuto HIKICHI ; Hiromasa OHIRA
Clinical Endoscopy 2023;56(1):107-113
Background/Aims:
Immune checkpoint blockade has recently been reported to be effective in treating microsatellite instability (MSI)-high tumors. Therefore, sufficient sampling of histological specimens is necessary in cases of unresectable pancreatic cancer (UR-PC). This multicenter study investigated the efficacy of endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) using a Franseen needle for MSI evaluation in patients with UR-PC.
Methods:
A total of 89 patients with UR-PC who underwent endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) or EUS-FNB using 22-G needles at three hospitals in Japan (2018–2021) were enrolled. Fifty-six of these patients (FNB 23 and FNA 33) were followed up or evaluated for MSI. Patient characteristics, UR-PC data, and procedural outcomes were compared between patients who underwent EUS-FNB and those who underwent EUS-FNA.
Results:
No significant difference in terms of sufficient tissue acquisition for histology was observed between patients who underwent EUS-FNB and those who underwent EUS-FNA. MSI evaluation was possible significantly more with tissue samples obtained using EUS-FNB than with tissue samples obtained using EUS-FNA (82.6% [19/23] vs. 45.5% [15/33], respectively; p<0.01). In the multivariate analysis, EUS-FNB was the only significant factor influencing the possibility of MSI evaluation.
Conclusions
EUS-FNB using a Franseen needle is desirable for ensuring sufficient tissue acquisition for MSI evaluation.